Such RCTs should include priority endpoints such as asthma control and exacerbation rates assessed by validated questionnaires (ACT, AQLQ, mini-AQLQ, ACQ), inflammatory asthma biomarkers (total IgE, FeNO, eosinophil count), and lung function parameters (PEF, FEV1, FVC, FEV1/FVC). This evidence concerns the gene IGHE and asthma.